Clinical trial

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

NCT04193059

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2019-12-20

PhasePHASE3

Study timeline

Study start (actual)2019-12-20Date precision: day

Registry last updated2025-11-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

EpirubicinDRUG · verified · RxNorm: epirubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04193059 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.